Trials / Completed
CompletedNCT01594970
A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 800 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of bimatoprost 0.01% in subjects with elevated intraocular pressure (IOP) due to primary open-angle glaucoma (POAG) or ocular hypertension (OH).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bimatoprost 0.01% | 1 drop in the affected eye(s), administered in the evening for 12 weeks. |
Timeline
- Start date
- 2012-03-01
- Primary completion
- 2013-01-01
- Completion
- 2013-01-01
- First posted
- 2012-05-09
- Last updated
- 2014-01-28
- Results posted
- 2014-01-28
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01594970. Inclusion in this directory is not an endorsement.